Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation

Paulina Liberman, Meghan K. Berkenstock, Bryn M. Burkholder, Benjamin C. Chaon, Jennifer E. Thorne

Research output: Contribution to journalArticle

Abstract

Purpose: To report the outcomes of the escalation of adalimumab (ADA) dose for refractory ocular inflammatory diseases. Methods: A retrospective case series of 15 patients (29 eyes) diagnosed with ocular inflammatory disease, including uveitis and scleritis, which was not adequately controlled with standard, every other week ADA dosing, leading to an escalation to weekly dosing. Results: Ten of fifteen patients escalated to weekly ADA achieved control of their inflammation; neither of the two patients increased for control of cystoid macular edema (CME) had resolution and required regional corticosteroids. One patient discontinued weekly ADA due to serious infection. The median length of follow up was 12 months. Conclusion: Our series suggests that the escalation of ADA can be a useful strategy for treating recalcitrant ocular inflammation, but may not be adequate to treat refractory CME.

Original languageEnglish (US)
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • Adalimumab
  • escalation
  • interval
  • uveitis
  • weekly

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation'. Together they form a unique fingerprint.

  • Cite this